Cabot Co. (NYSE:CBT) Holdings Increased by Barclays PLC

Barclays PLC increased its holdings in shares of Cabot Co. (NYSE:CBT - Free Report) by 38.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 156,908 shares of the specialty chemicals company's stock after purchasing an additional 43,294 shares during the period. Barclays PLC owned 0.29% of Cabot worth $14,327,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in shares of Cabot in the fourth quarter worth about $26,000. EverSource Wealth Advisors LLC grew its position in Cabot by 37.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 808 shares of the specialty chemicals company's stock valued at $74,000 after acquiring an additional 219 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Cabot by 10.7% during the fourth quarter. GAMMA Investing LLC now owns 1,348 shares of the specialty chemicals company's stock valued at $123,000 after purchasing an additional 130 shares during the period. Manchester Capital Management LLC lifted its position in shares of Cabot by 1,685.1% during the fourth quarter. Manchester Capital Management LLC now owns 1,678 shares of the specialty chemicals company's stock worth $153,000 after purchasing an additional 1,584 shares in the last quarter. Finally, KBC Group NV increased its stake in Cabot by 43.1% during the 4th quarter. KBC Group NV now owns 2,046 shares of the specialty chemicals company's stock worth $187,000 after buying an additional 616 shares during the period. 93.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CBT has been the subject of several recent analyst reports. StockNews.com upgraded Cabot from a "hold" rating to a "buy" rating in a research note on Thursday, April 17th. UBS Group reduced their price target on Cabot from $93.00 to $83.00 and set a "neutral" rating for the company in a report on Monday, April 7th. JPMorgan Chase & Co. dropped their price objective on Cabot from $105.00 to $85.00 and set an "underweight" rating on the stock in a report on Friday, February 21st. Finally, Mizuho reduced their target price on Cabot from $122.00 to $110.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th.

Cabot Stock Performance

CBT stock traded down $0.82 during trading on Friday, hitting $78.70. 54,286 shares of the company's stock traded hands, compared to its average volume of 426,857. The stock has a market capitalization of $4.27 billion, a price-to-earnings ratio of 10.45, a price-to-earnings-growth ratio of 0.74 and a beta of 1.04. Cabot Co. has a 52 week low of $73.63 and a 52 week high of $117.46. The stock has a fifty day moving average price of $82.11 and a two-hundred day moving average price of $94.03. The company has a quick ratio of 1.29, a current ratio of 2.00 and a debt-to-equity ratio of 0.72.

Cabot (NYSE:CBT - Get Free Report) last announced its quarterly earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.74 by $0.02. Cabot had a net margin of 10.60% and a return on equity of 26.79%. As a group, equities analysts anticipate that Cabot Co. will post 7.57 EPS for the current fiscal year.

Cabot Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.